DPP4 and Stroke: Although the effect of pioglitazone compared with DPP-4 inhibitors on cardiovascular outcomes has not been previously reported, a meta-analysis of 19 trials comparing pioglitazone with a placebo or other OAs found that pioglitazone was associated with a significantly lower risk of stroke and the composite of MI, stroke, or death [31].